Actinic (Solar) Keratosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Actinic Keratosis Pipeline Drugs Market Overview

An actinic keratosis, also known as solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck, or any other areas of the body frequently exposed to the sun. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, blue or light-colored eyes, and a weak immune system because of chemotherapy, chronic leukemia, AIDS, or organ transplant medications.

The Actinic Keratosis pipeline market research report provides comprehensive information on the therapeutics under development for Actinic Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Actinic Keratosis and features dormant and discontinued projects.

Key Targets in the Actinic Keratosis Pipeline Products Market

The key targets in the Actinic Keratosis pipeline products market are Tubulin, Tyrosine Protein Kinase CSK, Cannabinoid Receptor 2, Tumor Necrosis Factor Receptor Superfamily Member 1A, Tumor Necrosis Factor Receptor Superfamily Member 6, Cannabinoid Receptor 1, Caspase 9, Cytosolic Phospholipase A2, DNA, Epidermal Growth Factor Receptor, and others.

Actinic Keratosis Pipeline Products Analysis Market by Targets, 2022 (%)

For more target insights, download a free report sample

Key Mechanisms of Action in the Actinic Keratosis Pipeline Products Market

The key mechanisms of action in the Actinic Keratosis pipeline products market are Tubulin Inhibitor, Tyrosine Protein Kinase CSK Inhibitor, Cannabinoid Receptor 2 Agonist, Tumor Necrosis Factor Receptor Superfamily Member 1A Agonist, Tumor Necrosis Factor Receptor Superfamily Member 6 Agonist, Cannabinoid Receptor 1 Agonist, Caspase 9 Activator, Cytosolic Phospholipase A2 Inhibitor, DNA Synthesis Inhibitor, Epidermal Growth Factor Receptor Inhibitor, and others.

Actinic Keratosis Pipeline Products Market Analysis by Mechanisms of Action, 2022 (%)

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the Actinic Keratosis Pipeline Products Market

The key routes of administration in the Actinic Keratosis pipeline products market are topical, oral, cutaneous, inhalational, intravenous, parenteral, transdermal, intraperitoneal, intratumor, intravesical, and others.

Actinic Keratosis Pipeline Products Market Analysis by Routes of Administration, 2022 (%)

For more routes of administration insights, download a free report sample

Key Molecule Types in the Actinic Keratosis Pipeline Products Market

The key molecule types in the Actinic Keratosis pipeline products market are small molecule, enzyme, gene therapy, and monoclonal antibody.

Actinic Keratosis Pipeline Products Market Analysis by Molecule Types, 2022 (%)

For more molecule type insights, download a free report sample

Major Companies in the Actinic Keratosis Pipeline Products Market

Some of the major companies in the Actinic Keratosis pipeline products market are Athenex Inc, G&E Herbal Biotechnology Co., Ltd, Claradele Pharmaceuticals Inc, Coegin Pharma AS, Ingenew Pharmaceuticals Inc, Invion Ltd, Jupiter Wellness Inc, Laboratories Ojer Pharma SL, MedC Biopharma Ltd, and MediWound Ltd.

Athenex Inc: Athenex Inc (Athenex), formerly known as Kinex Pharmaceuticals Inc, is a biopharmaceutical company focused on the discovery, development and commercialization novel medicines and cell therapies for the treatment of cancers. The company’s orascovery products candidates include oral formulations of paclitaxel (Oraxol), irinotecan (Oratecan), and docetaxel (Oradoxel) for the treatment of metastatic breast, colorectal, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancers. Its Src kinase product candidates comprises KX-01, a novel orally administered small molecule compound for the treatment of actinic keratosis; and KX-02 for solid tumors.

Actinic Keratosis Pipeline Products Market Analysis by Companies, 2022 (%)

To know more about major companies, download a free report sample

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Actinic (Solar) Keratosis (Dermatology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Actinic (Solar) Keratosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Actinic (Solar) Keratosis (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.